Patents by Inventor Nicolas Bazan

Nicolas Bazan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11007199
    Abstract: This invention is directed to compositions, methods and kits that can be used for the treatment or amelioration of pain and fever.
    Type: Grant
    Filed: January 9, 2020
    Date of Patent: May 18, 2021
    Assignees: The Board of Supervisors of Louisiana State University and Agricultural and Mechanical College, University of Alcala De Hernares, South Rampart Pharma, LLC
    Inventors: Nicolas Bazan, Hernan Bazan, Julio Alvarez-Builla Gomez, Dennis Paul, Carolina Burgos Garcia
  • Publication number: 20210139846
    Abstract: This invention is directed towards genetically engineered cells, methods of making genetically engineered cells, and methods of using the same.
    Type: Application
    Filed: June 4, 2018
    Publication date: May 13, 2021
    Inventor: Nicolas Bazan
  • Publication number: 20200230087
    Abstract: This invention is directed to compositions, methods and kits that can be used for the treatment or amelioration of pain and fever.
    Type: Application
    Filed: January 9, 2020
    Publication date: July 23, 2020
    Inventors: Nicolas Bazan, Hernan Bazan, Julio Alvarez-Builla Gomez, Dennis Paul, Carolina Burgos Garcia
  • Publication number: 20200179393
    Abstract: This invention is directed to compositions, methods and kits that can be used for the treatment or amelioration of pain.
    Type: Application
    Filed: March 12, 2018
    Publication date: June 11, 2020
    Inventors: Nicolas BAZAN, Hernan BAZAN, Julio ALVAREZ-BUILLA, Dennis PAUL, Carolina BURGOS
  • Publication number: 20200032202
    Abstract: The invention is directed to a cell culture medium composition wherein the composition comprises an effective amount of: valproic acid; a GSK-3 inhibitor; a TGFPRI inhibitor; Forskolin; a JNK inhibitor; a protein kinase C (PKC) inhibitor; a Rho-associated, coiled-coil containing protein kinase (ROCK) inhibitor; at least one omega-3 fatty acid; a nutrient source, and any combination thereof.
    Type: Application
    Filed: April 4, 2018
    Publication date: January 30, 2020
    Inventors: Nicolas Bazan, Filipe Muhale
  • Publication number: 20070218105
    Abstract: The topical administration of a combination of nerve growth factor (NGF) and docosahexaenoic acid (DHA) has been discovered to synergistically increase the effects of NGF in re-innervating the cornea. This enhancement in corneal nerve re-growth will yield a faster anatomical and functional recovery after PRK or LASIK surgeries. Using rabbits, the application of NGF and DHA resulted in increased corneal nerve surface area, increased epithelial proliferation, and decreased rose bengal staining as compared with NGF, DHA, or vehicle control individually. The topical application of NGF plus DHA in accelerating the re-innervation after PRK or LASIK, will help avoid or alleviate the symptoms of dry eye or other neurotrophic keratopathies due to corneal injuries. The topical application can be by using a corneal shield or lens. This treatment will also be useful in other corneal abnormalities including those caused by chemical burn, congenital corneal neuropathy, or acquired corneal neuropathy.
    Type: Application
    Filed: September 16, 2005
    Publication date: September 20, 2007
    Inventors: Salomon Esquenazi, Haydee Bazan, Nicolas Bazan
  • Publication number: 20070161072
    Abstract: The present invention includes the characterization of the DGK? gene and the generation of screening methods for compounds that inhibit the function of DGK?. The DGK family of enzymes occupies a signaling crossroads since they catalyze the phosphorylation of DAG to produce PA. Both the substrate (DAG) and the product (PA) of this reaction are key factors in intracellular signaling, making the regulation of DGK? activity important to understand and control. DGK? ?/? mice were also generated and studied to assist in understanding the function of DGKs in regulating cellular signaling. DGK? displays selectively for 20:4-DAG and is highly expressed in different areas of the brain, including Purkinje cells in the cerebellum, hippocampal interneurons, and the Pyramidal neurons in the CA3 region of the hippocampus.
    Type: Application
    Filed: February 23, 2007
    Publication date: July 12, 2007
    Inventors: Stephen Prescott, Matthew Topham, Nicolas Bazan, Elena Rodriguez de Turco
  • Publication number: 20070042953
    Abstract: The infusion of an albumin-docosahexaenoic acid (DHA) complex was shown to inhibit the progression of kindling epileptogenesis. This was shown in mice using kindling as the experimental epilepsy model. The DHA-albumin complex was shown to affect the activity of the brain when administered intraperitoneally. This therapy could also be administered intravenously. This therapy would also be effective against chronic epilepsy.
    Type: Application
    Filed: October 18, 2005
    Publication date: February 22, 2007
    Inventors: Nicolas Bazan, Alberto Musto, Victor Marcheselli
  • Publication number: 20060276373
    Abstract: The invention provides a pharmaceutical composition useful in treating cerebral ischemia and traumatic cerebral injury. The pharmaceutical composition is also useful as a prophylactic treatment during surgical procedures wherein the potential for ischemic tissue damage is present. Also included in the invention is a method for preparing the pharmaceutical composition, as well as methods for treatment.
    Type: Application
    Filed: March 13, 2006
    Publication date: December 7, 2006
    Inventors: Nicolas Bazan, Myron Ginsberg, James Moises
  • Publication number: 20060263890
    Abstract: The invention is an electromagnetic probe used in conjunction with a ferrofluid containng M particles. The electromagnetic probe is used to steer M-particles to a desired location, or use the M particles for mixing the ferrofluid. The probe can be used in conjunction with a microscope, a micromanipulator, a catheter or endoscope.
    Type: Application
    Filed: May 17, 2005
    Publication date: November 23, 2006
    Inventors: Mark DeCoster, Nicolas Bazan
  • Publication number: 20060094654
    Abstract: The invention provides a pharmaceutical composition useful in treating cerebral ischemia and cerebral injury. The pharmaceutical composition is also useful as a prophylactic treatment during surgical procedures wherein the potential for ischemic tissue damage is present. Also included in the invention is a method for preparing the pharmaceutical composition, as well as methods for treatment.
    Type: Application
    Filed: September 23, 2005
    Publication date: May 4, 2006
    Inventors: Nicolas Bazan, Myron Ginsberg
  • Publication number: 20050164908
    Abstract: The invention provides a pharmaceutical composition useful in treating cerebral ischemia and cerebral injury. The pharmaceutical composition is also useful as a prophylactic treatment during surgical procedures wherein the potential for ischemic tissue damage is present. Also included in the invention is a method for preparing the pharmaceutical composition, as well as methods for treatment.
    Type: Application
    Filed: January 23, 2004
    Publication date: July 28, 2005
    Inventors: Myron Ginsberg, Nicolas Bazan
  • Publication number: 20050075398
    Abstract: A unique DHA product, 10, 17S-docosatriene (“Neuroprotectin D1” or “NPD1”), was found to provide surprisingly effective neuroprotection when administered right after an experimental stroke. Moreover, both nerve cells and retinal pigment epithelial (RPE) cells were found to synthesize 10,17S-docosatriene (NPD1) from DHA. NPD1 also potently counteracted H2O2/TNF? oxidative stress-mediated cell apoptotic damage. Under the same oxidative-stress conditions, NPD1 up-regulated the anti-apoptotic Bcl-2 proteins, Bcl-2 and Bcl-xL, and decreased expression of the pro-apoptotic proteins, Bad and Bax. Moreover, in RPE cells NPD1 inhibited oxidative stress-induced caspase-3 activation, IL-1?-stimulated human COX-2 promoter expression, and apoptosis due to N-retinylidene-N-retinylethanolamine (A2E). Overall, NPD1 protected both nerve and retinal pigment epithelial cells from cellular apoptosis and damage due to oxidative stress.
    Type: Application
    Filed: August 5, 2004
    Publication date: April 7, 2005
    Inventors: Nicolas Bazan, Charles Serhan, Victor Marcheselli, Pranab Mukherjee, Sebastian Barreiro, Walter Lukiw, Song Hong, Karsten Gronert, Alberto Musto